This common vaccine cuts heart risk nearly in half in new study

This groundbreaking finding, presented at the American College of Cardiology’s Annual Scientific Session (ACC.26), adds significant weight to the growing body of evidence suggesting that the shingles vaccine offers benefits extending far beyond the prevention of the painful rash. The research indicates a substantial reduction in major adverse cardiac events, including heart attacks, strokes, and heart failure, among a particularly vulnerable population already diagnosed with atherosclerotic heart disease.

Comprehensive Study Unveils Significant Cardioprotective Effects

The study, which reviewed an extensive dataset of over 246,822 adults in the United States, focused on individuals diagnosed with atherosclerotic heart disease. This condition, characterized by the buildup of plaque in the arteries, is a leading cause of cardiovascular morbidity and mortality globally. The findings underscore the potential for the shingles vaccine to act as a crucial preventative tool, not just against the herpes zoster virus, but also against severe cardiovascular complications in high-risk patients.

Dr. Robert Nguyen, a resident physician at the University of California, Riverside, and the study’s lead author, emphasized the cumulative nature of these discoveries. "This vaccine has been found over and over again to have cardioprotective effects for reducing heart attack, stroke and death," Dr. Nguyen stated. "Looking at the highest risk population, those with existing cardiovascular disease, these protective effects might be even greater than among the general public." His remarks highlight the unique significance of this study, which targeted a demographic already predisposed to cardiovascular events, thereby amplifying the observed benefits.

Methodology: A Deep Dive into a Large-Scale Analysis

To conduct this comprehensive analysis, researchers leveraged TriNetX, a sophisticated global federated research network that aggregates de-identified electronic health records from millions of Americans. This robust database allowed for the examination of adults aged 50 years or older who had been diagnosed with atherosclerotic disease between 2018 and 2025.

The study cohort was meticulously divided into two equal groups: 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine, and an equivalent number who had not been vaccinated. Crucially, both groups were carefully matched on a multitude of demographic factors and pre-existing health conditions, including age, gender, race, ethnicity, socioeconomic status, and common cardiovascular risk factors such as hypertension, diabetes, hyperlipidemia, and smoking history. This rigorous matching process was designed to minimize confounding variables, ensuring that any observed differences in outcomes could be more confidently attributed to the vaccination status.

Researchers then focused on tracking heart-related outcomes that occurred between one month and one year following vaccination (or within the same timeframe for the unvaccinated control group). The results were strikingly consistent across all measured cardiovascular endpoints. Vaccinated individuals exhibited a 46% lower likelihood of experiencing a major adverse cardiac event (MACE), a composite outcome typically including heart attack, stroke, and cardiovascular death. Furthermore, the all-cause mortality rate in the vaccinated group was 66% lower, suggesting a broader protective effect on overall health.

Specific reductions in individual cardiovascular events were equally compelling: the risk of heart attack plummeted by 32%, stroke by 25%, and heart failure by 25%. These figures are not merely statistically significant but represent a clinically meaningful impact on patient health and longevity. Dr. Nguyen underscored the magnitude of these reductions, comparing them favorably to the established health benefits derived from quitting smoking, a well-recognized cornerstone of cardiovascular disease prevention.

The Underlying Mechanism: How Shingles Impacts Heart Health

The connection between herpes zoster (shingles) and cardiovascular health has been an area of increasing scientific inquiry. Shingles, caused by the reactivation of the varicella-zoster virus (VZV) – the same virus responsible for chickenpox – typically manifests as a painful, blistering rash. While primarily known for its dermatological and neurological sequelae, including postherpetic neuralgia (long-lasting nerve pain), a growing body of research points to its systemic inflammatory effects.

Earlier studies have elucidated that an active shingles infection can trigger a cascade of inflammatory responses throughout the body. This inflammation can lead to endothelial dysfunction, impairing the inner lining of blood vessels. More critically, VZV reactivation has been implicated in promoting hypercoagulability, a state where the blood is more prone to forming clots. These clots can form in critical locations, such as the cerebral arteries (leading to stroke) or the coronary arteries (causing heart attacks). The systemic inflammatory burden and the increased thrombotic risk are believed to be the primary mechanisms by which shingles infections elevate the risk of acute cardiovascular events.

By preventing shingles infection, the vaccine effectively preempts this inflammatory cascade and the associated pro-thrombotic state. This mechanism provides a plausible biological explanation for the observed cardioprotective effects, suggesting that the vaccine doesn’t directly improve heart function but rather removes a significant trigger for cardiovascular deterioration.

Shingles Vaccines: A Public Health Imperative

The Centers for Disease Control and Prevention (CDC) currently recommends the shingles vaccine for all adults aged 50 years and older, as well as for younger individuals with weakened immune systems. This recommendation is primarily based on the vaccine’s efficacy in preventing shingles and its debilitating complications.

Historically, Zostavax was the first shingles vaccine available, approved in 2006. It was a live attenuated vaccine, meaning it contained a weakened form of the virus. While effective, its efficacy waned over time and it was not recommended for immunocompromised individuals. In 2017, Shingrix, a recombinant zoster vaccine, received approval. Shingrix is a non-live, subunit vaccine, making it suitable for a broader population, including those with compromised immune systems. It has demonstrated superior efficacy, typically over 90% against shingles, and long-lasting protection. The current study did not differentiate between the two vaccines in its primary analysis, given the timeframe of the data and the general goal of assessing "shingles vaccination" broadly. However, the high efficacy of Shingrix likely contributes significantly to the observed benefits.

Despite these clear recommendations, vaccination rates for shingles remain suboptimal in many populations. The present study’s findings provide a powerful new incentive for healthcare providers and public health officials to redouble efforts to promote shingles vaccination, especially among patients with existing heart disease.

The American College of Cardiology’s Annual Scientific Session (ACC.26)

The American College of Cardiology’s Annual Scientific Session is one of the most prestigious and anticipated events in cardiovascular medicine globally. Held annually, it brings together cardiologists, researchers, allied health professionals, and industry leaders from around the world to present and discuss the latest advancements in cardiovascular science, clinical practice, and public health. The conference features thousands of presentations, including groundbreaking clinical trials, new guidelines, and innovative research, often shaping the future of cardiology.

The presentation of Dr. Nguyen’s study at ACC.26 underscores its perceived importance and potential impact on clinical practice. Being selected for presentation at such a high-profile event signifies that the research has undergone rigorous peer review and is considered to contribute significantly to the understanding and management of cardiovascular disease. The session where Dr. Nguyen will present, "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," is scheduled for Monday, March 30, at 12:30 p.m. CT / 17:30 UTC in Posters, Hall E.

Broader Implications and Future Directions

The profound reductions in cardiovascular events observed in this study carry significant implications for public health and clinical cardiology. For individuals already battling atherosclerotic heart disease, any intervention that can substantially lower their risk of heart attack, stroke, or heart failure is invaluable. This research reinforces the notion that preventive strategies can come from unexpected avenues, expanding the toolkit available to clinicians.

From a public health perspective, increasing shingles vaccination rates could lead to a substantial reduction in the burden of cardiovascular disease, especially in an aging global population where both shingles and heart disease are prevalent. This could translate into fewer hospitalizations, reduced healthcare costs associated with managing acute cardiovascular events, and an overall improvement in quality of life for millions.

However, the study also acknowledges certain limitations inherent in observational research. One key consideration is the "healthy user bias." It is plausible that individuals who choose to get vaccinated may also engage in other healthier behaviors, such as adhering to medication regimens, exercising regularly, and maintaining a balanced diet. While the researchers meticulously adjusted for numerous health and socioeconomic factors – including problems related to housing, economic circumstances, social environment, employment status, education, and literacy – it remains challenging to completely eliminate the influence of unmeasured confounding variables. Despite this, the study’s massive sample size and robust statistical methodology provide compelling evidence for a meaningful association between shingles vaccination and reduced heart risk.

Furthermore, the analysis only tracked outcomes for the first year post-vaccination. While the observed benefits within this timeframe are substantial, the long-term effects warrant further investigation. Dr. Nguyen noted a previous study published in 2025 (likely a projection or typo for 2015/2020) which found that shingles vaccination was linked to a 23% reduction in cardiovascular events in generally healthy adults, with benefits potentially lasting up to eight years. This suggests that the protective effects may be durable, but direct, longer-term follow-up in the high-risk atherosclerotic heart disease population is crucial.

Future research could involve prospective randomized controlled trials (RCTs) to definitively establish causality, though such trials for vaccine efficacy against secondary outcomes are often complex and expensive. Additionally, studies exploring the precise immunological and inflammatory pathways involved in the cardioprotective effect could further refine our understanding and potentially lead to new therapeutic targets.

In conclusion, the findings presented at ACC.26 represent a critical advancement in understanding the broad health benefits of the shingles vaccine. They provide yet another compelling reason for adults, especially those with existing cardiovascular disease, to consider vaccination, reinforcing Dr. Nguyen’s assertion: "Vaccines are one of the most important medicines we have to prevent disease. Sometimes patients are unsure about whether they should get a vaccine or not, particularly in an age of disinformation. These results provide another reason for them to elect to get the vaccine." This research serves as a powerful reminder of the multifaceted value of vaccination in promoting not just specific disease prevention, but holistic health and longevity.